AbstractThe 2005 National Institute of Health (NIH) Consensus Conference outlined histopathological diagnostic criteria for the major organ systems affected by both acute and chronic graft-versus-host disease (GVHD). The 2014 Consensus Conference led to this updated document with new information from histopathological studies of GVHD in the gut, liver, skin, and oral mucosa and an expanded discussion of GVHD in the lungs and kidneys. The recommendations for final histological diagnostic categories have been simplified from 4 categories to 3: no GVHD, possible GVHD, and likely GVHD, based on better reproducibility achieved by combining the previous categories of “consistent with GVHD” and “definite GVHD” into the single category of “likely G...
Several international recommendations address the assessment of graft-versus-host disease (GvHD) aft...
AbstractThe complexity of chronic graft-versus-host disease (GVHD) and the lack of established resea...
: Positive results from recent clinical trials have significantly expanded current therapeutic optio...
AbstractThe 2005 National Institute of Health (NIH) Consensus Conference outlined histopathological ...
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosi...
Recognition of the earliest signs and symptoms of chronic graft-versus-host disease (GVHD) that lead...
AbstractThe 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for ...
AbstractThis consensus document is intended to serve 3 functions. First, it standardizes the criteri...
AbstractThis consensus document provides an update for pathologists and clinicians about the interpr...
Based on expert opinion and retrospective data the National Institutes of Health (NIH) Consensus Dev...
Historically, graft-versus-host disease (GVHD) beyond 100 days after hematopoi-etic cell transplanta...
Chronic graft-versus-host disease (GVHD) can be associated with significant morbidity, in part becau...
AbstractThe 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by th...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Historically, graft-versus-host disease...
AbstractChronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality ...
Several international recommendations address the assessment of graft-versus-host disease (GvHD) aft...
AbstractThe complexity of chronic graft-versus-host disease (GVHD) and the lack of established resea...
: Positive results from recent clinical trials have significantly expanded current therapeutic optio...
AbstractThe 2005 National Institute of Health (NIH) Consensus Conference outlined histopathological ...
The 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for diagnosi...
Recognition of the earliest signs and symptoms of chronic graft-versus-host disease (GVHD) that lead...
AbstractThe 2005 National Institutes of Health (NIH) Consensus Conference proposed new criteria for ...
AbstractThis consensus document is intended to serve 3 functions. First, it standardizes the criteri...
AbstractThis consensus document provides an update for pathologists and clinicians about the interpr...
Based on expert opinion and retrospective data the National Institutes of Health (NIH) Consensus Dev...
Historically, graft-versus-host disease (GVHD) beyond 100 days after hematopoi-etic cell transplanta...
Chronic graft-versus-host disease (GVHD) can be associated with significant morbidity, in part becau...
AbstractThe 2006 National Institutes of Health (NIH) Consensus paper presented recommendations by th...
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)Historically, graft-versus-host disease...
AbstractChronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality ...
Several international recommendations address the assessment of graft-versus-host disease (GvHD) aft...
AbstractThe complexity of chronic graft-versus-host disease (GVHD) and the lack of established resea...
: Positive results from recent clinical trials have significantly expanded current therapeutic optio...